Condition: Advanced Solid Tumors · Sponsor: AstraZeneca
The purpose of this study is to determine the subcutaneous (SC) dose that gives rilvegostomig exposure comparable to the intravenous (IV) exposure, and to evaluate the pharmacokinetics (PK) and safety of SC rilvegostomig in adult participants with advanced solid tumors previously treated with standard of care therapy for whom immunooncology (IO) monotherapy would be deemed appropriate by the investigator.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Huntersville, North Carolina, United States | Recruiting |
| Research Site | San Antonio, Texas, United States | Recruiting |
| Research Site | Fairfax, Virginia, United States | Recruiting |
| Research Site | Seoul, South Korea | Recruiting |
| Research Site | Seoul, South Korea | Recruiting |
| Research Site | Barcelona, Spain | Not Yet Recruiting |
| Research Site | Barcelona, Spain | Recruiting |
| Research Site | Madrid, Spain | Recruiting |
| Research Site | Madrid, Spain | Recruiting |
| Research Site | Newcastle upon Tyne, United Kingdom | Suspended |
| Research Site | Sutton, United Kingdom | Suspended |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07161414